Cargando…
CDK4/6 inhibition in cancer: the cell cycle splicing connection
Cyclin-dependent kinase −4 and −6 (CDK4/6) inhibitors are currently being assessed in clinical trials for the treatment of many cancers including melanoma. While investigating the mechanisms of CDK4/6 inhibitor resistance in melanoma, we uncovered a mechanism of action of these inhibitors in regulat...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816418/ https://www.ncbi.nlm.nih.gov/pubmed/31692881 http://dx.doi.org/10.1080/23723556.2019.1673643 |
| _version_ | 1783463367156957184 |
|---|---|
| author | Sheppard, Karen E. AbuHammad, Shatha |
| author_facet | Sheppard, Karen E. AbuHammad, Shatha |
| author_sort | Sheppard, Karen E. |
| collection | PubMed |
| description | Cyclin-dependent kinase −4 and −6 (CDK4/6) inhibitors are currently being assessed in clinical trials for the treatment of many cancers including melanoma. While investigating the mechanisms of CDK4/6 inhibitor resistance in melanoma, we uncovered a mechanism of action of these inhibitors in regulating the expression of both the mouse double minute 4 (MDM4) oncogene and tumor protein p53 (TP53). |
| format | Online Article Text |
| id | pubmed-6816418 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Taylor & Francis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-68164182020-09-28 CDK4/6 inhibition in cancer: the cell cycle splicing connection Sheppard, Karen E. AbuHammad, Shatha Mol Cell Oncol Author’s Views Cyclin-dependent kinase −4 and −6 (CDK4/6) inhibitors are currently being assessed in clinical trials for the treatment of many cancers including melanoma. While investigating the mechanisms of CDK4/6 inhibitor resistance in melanoma, we uncovered a mechanism of action of these inhibitors in regulating the expression of both the mouse double minute 4 (MDM4) oncogene and tumor protein p53 (TP53). Taylor & Francis 2019-10-17 /pmc/articles/PMC6816418/ /pubmed/31692881 http://dx.doi.org/10.1080/23723556.2019.1673643 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
| spellingShingle | Author’s Views Sheppard, Karen E. AbuHammad, Shatha CDK4/6 inhibition in cancer: the cell cycle splicing connection |
| title | CDK4/6 inhibition in cancer: the cell cycle splicing connection |
| title_full | CDK4/6 inhibition in cancer: the cell cycle splicing connection |
| title_fullStr | CDK4/6 inhibition in cancer: the cell cycle splicing connection |
| title_full_unstemmed | CDK4/6 inhibition in cancer: the cell cycle splicing connection |
| title_short | CDK4/6 inhibition in cancer: the cell cycle splicing connection |
| title_sort | cdk4/6 inhibition in cancer: the cell cycle splicing connection |
| topic | Author’s Views |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816418/ https://www.ncbi.nlm.nih.gov/pubmed/31692881 http://dx.doi.org/10.1080/23723556.2019.1673643 |
| work_keys_str_mv | AT sheppardkarene cdk46inhibitionincancerthecellcyclesplicingconnection AT abuhammadshatha cdk46inhibitionincancerthecellcyclesplicingconnection |